Samil Pharmaceutical Co Ltd

Samil Pharmaceutical Co Ltd exhibits a capital structure with a debt-to-equity ratio of 1.23, indicating a moderate reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.44 and negative net cash after subtracting total debt. Free cash flow is negative at -29.4 billion KRW, and operating cash flow is only 568 million KRW, suggesting limited capacity to fund operations or debt obligations without external financing. Profitability metrics are concerning, with a return on equity of -26.01% and a return on assets of -9.33%. These figures are well below the typical performance of the pharmaceutical industry, which generally maintains positive returns on equity and assets. The company's operating income is negative at -26.85 billion KRW, and net income is also negative at -34.66 billion KRW, indicating a significant decline in profitability. The company operates through two segments: Pharmaceuticals and Other. The Pharmaceuticals segment is the primary revenue driver, focusing on gastrointestinal, liver disease, and ophthalmic treatments. The Other segment includes related services and rental services. Revenue concentration data is not provided, but the company's reliance on pharmaceutical sales suggests a moderate level of exposure to market and regulatory risks in the healthcare sector. Growth trajectory is mixed. The company's revenue for the latest period is 210.25 billion KRW, but there is no clear indication of growth in the near term. Analysts have provided a mean price target of 13,000 KRW, with a single "Buy" recommendation and no "Strong Buy" or "Hold" ratings. The lack of analyst optimism suggests limited confidence in the company's ability to improve its financial performance in the near future. Risk factors include liquidity constraints and the potential for further debt accumulation. The company's liquidity risk is rated as medium, and the risk assessment highlights that net cash is negative after subtracting total debt. There is no indication of dilution potential in the near term, as shares outstanding for both basic and diluted are the same at 21.23 million. However, the company's negative net income and operating cash flow suggest a need for external financing, which could lead to future dilution. Recent events include the publication of the latest financial snapshot, which shows a significant decline in profitability and liquidity. There are no recent filings or transcripts provided in the data, but the financial results indicate a challenging operating environment. The company's focus on developing new drugs for ophthalmic diseases, liver diseases, and circulatory and musculoskeletal conditions may provide long-term growth opportunities, but these are not reflected in the current financial performance.